CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
Bleicher Fonti & Auld LLP (BFA Law) announced a securities fraud class action against Capricor Therapeutics and senior executives, with a September 28, 2026 lead plaintiff deadline. The suit alleges Capricor made false statements about Deramiocel and undisclosed post-hoc changes to the statistical analysis plan in its BLA; the FDA had not agreed to those changes before resubmission. CAPR fell 64.5% on July 27, 2026 after FDA briefing documents raised concerns, and dropped another 36% after an advisory panel voted 9-3 that evidence did not support Deramiocel's efficacy.
Key figures
- Court
- U.S. District Court for the Southern District of California
- Case caption
- Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385
- Stock drop pct
- 64.5%
- Lead plaintiff deadline
- September 28, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.